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This study investigated the performance of Cepheid Xpert human papillomavirus (HPV) assay in South
African human immunodeﬁciency virus (HIV)-infected women and compared its performance with that
of hybrid capture-2 (hc2). Methods: Stored cervical specimens from HIV-infected women that had pre-
viously been tested using hc2 were tested using Xpert. Results: The overall HR-HPV prevalence was found
to be 62.0% (720/1161) by Xpert and 61.2% (711/1161) by hc2. 13.6% (158/1161) were HPV16 positive, 18.8%
(218/1161) were HPV18/45, 37.3% (434/1161) were HPV31/33/35/52/58, 12.7% (147/1161) were HPV51/59
and 23.3% (270/1161) were HPV39/68/56/66. Overall agreement with hc2 was 90%; Cohen’s kappa was
0.78 (95% CI 0.74–0.82) indicating substantial agreement. Detection of HPV16, HPV18/45, and HPV31/33/
35/52/58 were independently associated with cervical intraepithelial neoplasia (CIN)2þ (Po0.0001
for each); while HPV51/59 and HPV39/68/56/66 were not. Women infected with HPV16, HPV18/45 or
HPV31/33/35/52/58 were found to have signiﬁcantly higher amounts of HPV DNA detected for those with
CIN2þ compared to those without CIN2þ , Po0.0001 for each. Xpert and hc2 were similarly sensitive
(88.3% and 91.5%, respectively) and speciﬁc (48.4% and 51.0%) for CIN2þ and CIN3 (sensitivity: 95.8% and
97.9%; speciﬁcity: 41.4% and 42.8%). Conclusions: Xpert is a promising screening test in HIV-infected
women that performs similarly to hc2.
& 2016 The Auhtors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In sub-Saharan Africa, cervical cancer is the most common
cancer among women [1,2]. The high burden of cervical cancerB.V. This is an open access article u
se and Molecular Medicine,
n, Anzio Road, Observatory,
6681.
.A. Mbulawa),
evin@wits.ac.za (S. Levin),
il.unc.edu (J.S. Smith),cases and death in sub-Saharan Africa is due to the lack of effective
cervical cancer prevention programs. Cervical screening pro-
grammes are under-resourced and understaffed reducing women’s
access to these programmes. Limited human resources and clinic
capacity, as well as patient costs (including travel, child care, and
missed wages) are among the many challenges faced. Women in
resource-limited countries often present with invasive cervical
disease in its most advanced stage, reducing survival.
Visual inspection with acetic acid (VIA) has been used in many
resource-limited countries as a way of expanding cervical cancer
screening [3–5]. However, VIA as a screening test has lower efﬁ-
cacy in reducing cervical cancer than that of cervical cytology and
HR-HPV molecular testing [3]. Persistent infection with high-risk
(HR) human papillomavirus (HPV) is necessary for the develop-
ment of cervical cancer and therefore HR-HPV testing is con-
sidered an alternative test to cytology or VIA or used in variousnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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testing for HR-HPV types has been found to be more sensitive but
less speciﬁc for detection of cervical intraepithelial neoplasia-2/3
(CIN-2/3) when compared with cervical cytology [8,9].
Currently available HPV assays are batch tests, requiring skilled
laboratory personnel and taking several hours to complete. The
Cepheid Xpert HPV assay (Cepheid Sunnyvale, CA) is a qualitative,
real time polymerase chain reaction assay detecting 14 HR-HPV
DNA. A single Xpert HPV test can be completed in one hour,
allowing same day screening, diagnosis and treatment [10]. Xpert
HPV demonstrates good clinical performance in identifying
women with CIN2/3 and it was found to have similar performance
as other FDA approved HR-HPV tests among human
immunodeﬁciency virus (HIV)-uninfected women [10–12]. Point-
of-care HR-HPV testing may improve the management and control
of cervical cancer.
A high proportion of people living with HIV reside in sub-
Saharan Africa [13]. Multiple HPV infections and persistent HPV
infection are signiﬁcantly higher in HIV-positive women than HIV-
negative women [14–16]. Among HIV-infected women the pro-
gression from persistent infection to CIN2/3 occurs within a
shorter period of time and occurs more frequently than in HIV-
negative women [15,17,18]. The association between highly active
antiretroviral therapy (HAART) and HPV infection and cervical
cancer is controversial with conﬂicting reports [15]. According to
the systematic review evaluating the impact of HAART on inci-
dence of cancers; the use of HAART does not seem to decrease the
risk of developing cervical cancer [19].
In South Africa there are no standard guidelines on so-called
“screen-and-treat” methods for cervical cancer prevention in
either HIV-infected or -uninfected women. Identiﬁcation of opti-
mal cervical cancer screening methods among HIV-positive
women is necessary, particularly in the context of high HIV dis-
ease burden in settings like South Africa. Therefore, the aim of the
study was to investigate the performance of Cepheid Xpert HPV
assay in HIV-infected South African women and compare its per-
formance with that of Digene hybrid capture 2 (hc2) (an FDA
approved test).2. Methods
2.1. Study population and design
The current study used stored samples obtained from the
VICAR-1 study conducted between November 2009 and August
2011 in Johannesburg, South African. VICAR-1 study was a cohort
study of HIV-infected, South African women evaluating 3 cervical
cancer screening tests: hc2 test for HR-HPV, cervical cytology, and
VIA [20]. Human Research Ethics Committee of University of
Witwatersrand and University of Cape Town approved all aspects
of the study. All study participants provided written informed
consent. For the current analysis, stored cervical specimens
(n¼1193) from HIV-infected women that had previously been
tested using hc2 were tested using the Xpert HPV test.
2.2. Pathology results
The cytology and histology were reviewed as part of standard
of care by the National Health Laboratory Services (NHLS). The
NHLS undergoes routine accreditation by the South African
National Accreditation System and the pathologists undergo reg-
ular proﬁciency testing through the Royal College of Pathologist of
Australasia Quality Assurance scheme. In addition there is a 100%
second review of all negative Pap smears by a second cyto-
technologist and all abnormal Pap smears are reviewed by a seniorcytologist or pathologist. The cytology readings from NHLS have
previously gone under an external blinded review at University of
North Carolina with 80–85% concordance of results; if clinically
indicated, discrepant cytological and histological results were
reviewed and second procedure done [21,22].
2.3. HPV genotyping
Cervical specimens were collected with a Digene cervical
sampler and stored in 1 ml Digene transport medium buffer and
stored at 80°C. It is important to note that Digene transport
medium buffer is not a manufacturer’s approved collection med-
ium for the Xpert HPV. The ThinPrep transport medium is one of
the approved collection medium and is 20 ml while Digene
transport medium is 1 ml. A total of 100 ml cervical sample was
transferred to 950 ml phosphate buffered saline and 1000 ml of
diluted specimen was used to run Cepheid Xpert HPV according to
manufacturer’s instructions. Xpert HPV gives results from 6 sepa-
rate channels: (a) sample adequacy control (SAC), (b) P1-HPV16,
(c) P2-HPV18/45, (d) P3-HPV31/33/35/52/58, (e) P4-HPV51/59 and
(f) P5-HPV39/68/56/66.
2.4. Statistical analysis
The relationship between HPV detection in the 5 Xpert chan-
nels and CIN2/3 was determined by univariable and multivariable
logistic regression. All 5 HPV channels were included in the mul-
tivariable model. We quantiﬁed HPV DNA using the cycle thresh-
old (Ct) normalised with the SAC Ct (HPV DNA Ct/SAC Ct) as
described previously [11]. The relationship of the normalized Ct
value to the presence of CIN2þ was determined using the Stu-
dent’s t-test. The test performance characteristics for Xpert and
hc2 are weighted to adjust for veriﬁcation bias as was done for the
original cohort description [20,23]. All statistical analyses were
conducted using SAS 9.4 (Cary, North Carolina, USA).3. Results
A total of 1202 women were enroled in the parent screening
study between November 2009 and August 2011. These women
were recruited from a HIV treatment clinic Themba Lethu Clinic
located in a tertiary academic hospital in Johannesburg. Almost all
of the women (98.1%) considered themselves Black African and
had median age of 38 years (IQR 32–43) with a median CD4 count
of 394 cells/μL. The majority of women (93.1%) were on HAART
and approximately 83% had HIV plasma viral loads under
400 copies/ml.
Of these 1202 women, 1193 participants were included in the
VICAR-1 analysis (9 were excluded due to incomplete test results:
6 had inadequate or no cytology and 3 had invalid hc2 HPV or VIA
results). Of these, 1161 (97%) have valid Xpert HPV results (10 had
no sample available for analysis, 22 had samples tested but no
results were obtained because of technical issues with the Xpert
machine and not enough specimen was available for a re-run). The
HR-HPV prevalence was found to be 62.0% (720/1161) for Xpert
and 61.2% (711/1161) for hc2. 13.6% of women (158/1161) were
HPV16 positive, 18.8% (218/1161) were HPV18/45, 37.3% (434/1161)
were HPV31/33/35/52/58, 12.7% (147/1161) were HPV51/59 and
23.3% (270/1161) were HPV39/68/56/66 (Table 1). Multiple HPV
types were observed in 29.5% (342/1161) of specimens and a single
HPV type in 32.6% (378/1161) of specimens. HR-HPV positivity on
both Xpert [odds ratio (OR): 6.9, 95% conﬁdence interval (CI): 4.7–
9.6, Po0.0001] and hc2 (OR: 11.0, 95% CI: 7.4–16.6, Po0.0001)
were signiﬁcantly associated with CIN2þ (Table 1). HPV16 was
found to be independently associated with CIN2þ (OR: 6.8, 95%
Table 1
Observed association of high-risk human papillomavirus with cervical intraepithelial lesions in HIV-seropositive women.
Prevalence, N (%) CIN2þ prevalence (test positive vs. test
negative)
Univariate association with CIN2þ , OR [95%
CI]
Multivariate
hc2 positive 727 (61%) 42% vs. 6.2% 11 [7.4–16.6]n n/a
Xpert HPV positive 720 (62%) 39.2% vs. 8.8% 6.9 [4.7–9.6]n n/a
HPV16 158 (13.6%) 68.3% vs. 22.3% 7.5 [5.2–10.9]n 6.8 [4.5–10.1]n
HPV18/45 218 (18.8%) 45.1% vs. 24.2% 2.6 [1.9–3.5]n 2.5 [1.8–3.4]n
HPV31/33/35/52/58 434 (37.3%) 45.5% vs. 17.5% 3.9 [3.0–5.1]n 3.5 [2.6–4.6]n
HPV51/59 147 (12.7%) 42.1% vs. 26.1% 2.1 [1.4–2.9]n 1.3 [0.87–2.0], P¼0.19
HPV39/68/56/66 270 (23.3%) 37.2% vs. 25.1% 1.8 [1.3–2.3]n 1.2 [0.89–1.7], P¼0.20
n Po0.0001. CIN: cervical intraepithelial neoplasia; n/a: not applicable; hc2: hybrid capture-2; HPV: human papillomavirus.
Table 2
The performance characteristics for various human papillomavirus screening algorithms.
CIN2þ CIN3
Sensitivity Speciﬁcity PPV NPV Sensitivity Speciﬁcity PPV NPV
Digene
hc2
91.5% (87.2–95.8) 51.0% (47.6–54.5) 42.1% (38.4–45.8) 93.9% (90.7–97.1) 97.9% (95.1–100 ) 42.8% (39.8–45.7) 14.4% (11.8–17.0) 99.5% (98.9–100 )
Xpert 88.3% (83.6–93.0) 48.4% (44.9–51.9) 40.1% (36.5–43.8) 91.3% (87.6–95.0) 95.8% (91.8–99.9) 41.4% (38.4–44.4) 13.9% (11.3–16.5) 99.0% (98.0–100)
HPV16 31.5% (26.3–36.7) 93.5% (91.8–95.2) 65.5% (56.7–74.2) 77.7% (74.9–80.5) 43.0% (33.3–52.8) 89.4% (87.5–91.3) 28.8% (21.0–36.5) 94.0% (92.5–95.5)
HPV18/45 30.1% (25.0–35.3) 85.6% (83.2–88.0) 45.0% (38.1–51.8) 75.8% (72.8–78.9) 32.3% (23.1–41.5) 82.5% (80.2–84.8) 15.5% (10.5–20.4) 92.5% (90.8–94.2)
HPV31/
33/35/
52/58
61.1% (55.4–66.8) 71.9% (68.8–75.0) 45.9% (41.0–50.7) 82.6% (79.4–85.8) 63.9% (54.4–73.4) 65.3% (62.4–68.1) 15.4% (11.9–18.8) 94.8% (93.1–96.5)
HPV51/59 18.8% (14.5–23.2) 89.7% (87.6–91.8) 41.7% (33.5–49.9) 73.9% (70.9–76.8) 16.2% (9.00–23.5) 87.7% (85.7–89.7) 11.5% (6.2–16.9) 91.4% (89.6–93.1)
HPV39/
68/56/
66
33.6% (28.3–38.9) 80.7% (78.0–83.5) 40.7% (34.7–46.7) 75.6% (72.4–78.8) 36.7% (27.3–46.2) 78.0% (75.5–80.5) 14.2% (9.9–18.5) 92.6% (90.8–94.3)
PPV: positive predictive value; NPV: negative predictive value; CIN: cervical intraepithelial neoplasia; hc2: hybrid capture-2; Xpert: considered positive if any channel is
positive; HPV: human papillomavirus.
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45 (OR: 2.5, 95% CI: 1.8–3.4, Po0.0001) and HPV31/33/35/52/58
(OR: 3.5, 95% CI: 2.6–4.6, Po0.0001); but not for HPV51/59 (OR:
1.3, 95% CI: 0.87–2.0, P¼0.19) and HPV39/68/56/66 (OR: 1.2, 95%
CI: 0.89–1.7, P¼0.20).
Overall agreement was 90% where 385 (33%) were negative by
both tests and 655 (56%) were positive by both tests. The agree-
ment beyond chance (Cohen’s kappa) was 0.78 (95% CI: 0.74–0.82),
indicating excellent agreement. Samples with discordant results
had similar cellularity when compared with those with con-
cordant results as measured by the Xpert reporter gene cycle
threshold (Ct; 31.6 cycles for discordant samples compared to 31.5
for concordant samples, not statistically signiﬁcant). Discordant
samples had lower amounts of HPV DNA detected. The 56 samples
that were positive by hc2 and negative by Xpert, had lower rela-
tive light units (RLU, an indication of lower HPV viral load) as
compared to samples where both tests were positive (2.3 log 10
RLU vs. 5.0 log 10 RLU, Po0.0001). Similarly, the 65 samples that
were Xpert positive and hc2 negative had lower numbers of HPV
channels positive by Xpert (HR-HPV was detected in an average of
1.8 out of 5 channels for Xpert positive/hc2 positive vs. 1.1 chan-
nels for Xpert positive/hc2 negative, Po0.0001). In addition, lower
levels of HPV DNA as measured by higher Ct values were seen for
all 5 HPV channels.
The relationship between the amount of HR-HPV DNA detected
and the prevalence of CIN2þ was investigated. Among women
infected with HPV16, HPV18/45 or HPV31/33/35/52/58, women
with CIN2þ detected were found to have signiﬁcantly higher
amounts of HPV DNA detected compared to those without CIN2þ ,
Po0.0001 for each (Supplementary 1). The performance of Xpert
and hc2 for CIN2þ and CIN3 are presented in Table 2. Xpert andhc2 were similarly sensitive (88.3% and 91.5%, respectively) and
speciﬁc (48.4% and 51.0%, respectively) for CIN2þ and CIN3 (sen-
sitivity: 95.8% and 97.9%, respectively; speciﬁcity: 41.4% and 42.8%,
respectively). The presence of HPV16 by Xpert increased the spe-
ciﬁcity for CIN2þ from 48.4% to 93.5% and for CIN3 from 41.4%
to 89.4%.4. Discussion
To our knowledge this is the ﬁrst published report on perfor-
mance of Xpert HPV assay among HIV-positive women conducted
in a resource-limited country. Xpert HPV results were found to be
comparable to the results by hc2 and substantial agreement
between the two assays was demonstrated. Discordant results
between the assays were related to lower HPV DNA amounts as
indicated by lower RLU in hc2 and high Ct values in Xpert. It is
important to note that the samples that were HPV negative by
Xpert (including those that were hc2 positive) were adequate
samples according to the internal SAC control. A number of spe-
cimens were Xpert or hc2 negative but CIN2þ positive. These
observations may indicate false negative HR-HPV results, histology
false positive or the observed CIN2þ maybe due to HPV types that
are not detected by Xpert or hc2 [24,25].
HPV16 positivity by Xpert was strongly associated with CIN2þ .
Einstein et al. also reported strong association of HPV16 detected
by Xpert with CIN2þ and this association was comparable with
HPV16 detected by cobas. HPV18/45 and HPV31/33/35/52/58 were
also associated with CIN2þ however the positive predictive value
was not as high [10]. These observations conﬁrm the strong
association between HPV16 with high grade lesions and cervical
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detection should be a strong indication for a test and treat
approach in resource limited settings. HPV viral load was higher in
HPV infected women with CIN2þ compared to CIN2þ negative.
High HPV viral load is reported to be the predictor of abnormal
cervical cytology [26,27]. Future studies should investigate with
HPV quantitation can be used to increase the speciﬁcity for CIN2þ .
Both Xpert and hc2 were found to be similarly sensitivity and
speciﬁcity in contrast to the study reported by Einstein et al.
where hc2 was found to be more speciﬁc than Xpert while Xpert
was more sensitive than hc2. The HIV status was not speciﬁed in
Einstein et al. study. The negative predictive value (NPV) of Xpert
and hc2 for CIN2þ is similar to the one reported by Einstein et al.
however the current report presents higher PPV by both Xpert
(40.1% vs. 29%) and hc2 (42.1% vs. 23%). This is likely due to the
greater likelihood of HR-HPV infection causing CIN2þ in HIV-
infected women as compared to HIV-uninfected women. The dif-
ferences between this report and Einstein et al. could also be due
to different type of samples used; as they used ThinPrep specimen
while the current report used the specimen stored in Digene
transport media [10].
Limitations of the study: Specimens used were cervical speci-
mens stored in Digene Specimen Transport Medium that had been
frozen and thawed several times. The type of specimen used in
this study is not the type approved for use with the Xpert HPV
assay; ThinPrep (Hologic, Marlborough, MA) is the approved
transport medium. This may have led to biased results as com-
pared to processing samples according to the manufacturer’s
instructions. Despite these limitations the Xpert HPV assay was
still found to perform similarly to hc2. Additionally, we used
stored specimens and are therefore unable to comment on Xpert
HPV as a point-of-care test. Additional studies are needed to
evaluate Xpert HPV as it will be used in clinical practice.
The GeneXpert technology is been widely used in South Africa
for Mycobacterium tuberculosis screening [28–30]. Therefore cer-
vical cancer screening using Xpert HPV technology may be mod-
elled after programmes and systems developed for Xpert TB
testing. Point-of-care HPV screening and treatment is expected to
increase the screening coverage and reduce attrition from care.
However it should be noted that screening needs to be linked to
treatment programmes at the clinics which comes with additional
challenges. In conclusion, we demonstrate that Xpert is sensitive
and speciﬁc for detecting CIN2þ and CIN3; and its performance is
similar to hc2. Xpert is a promising cervical cancer screening test
for HIV-infected women. Additional studies incorporating DNA
quantiﬁcation and detection of speciﬁc HR-HPV types into
screening modalities for HIV-infected women are needed, as are
real-world evaluations of point-of-care HPV assays that may be
able to be incorporated into screen-and-treat cervical screening
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